International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

BMS Press Release Graphic

Bristol Myers Squibb has announced the U.S. Food and Drug Administration’s (FDA) approval of Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years. The approval follows the results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which proved the efficacy of once-daily Sotyktu compared to placebo and twice-daily Otezla® (apremilast) in achieving clearer skin. IPC Councilor April Armstrong, MD, MPH, was quoted in the press release stating, “Sotyktu has the potential to become the new standard of care oral treatment for people with moderate to severe plaque psoriasis, given its profile in helping patients achieve clearer skin as demonstrated in the POETYK PSO clinical program.”

Bristol myers squibb logo small

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Tags

Recent Posts

Bachelez - New President Announcement

IPC Appoints New President for 2023

Think Tank Congress

Focus on Psoriasis: A Report from the 2022 IPC Think Tank – Miami

IPC Volunteer of the year 2022

Meet Our 2022 Volunteers of the Year

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.